Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis

NCT00382629 is registered in ClinicalTrials.gov with Bayhill Therapeutics as lead sponsor.

NCT NCT00382629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00382629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
Lead sponsor
Bayhill Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
June 30, 2007
Enrollment
252
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis